Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Cassava sciences, inc. save search
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
Published: 2024-02-07 (Crawled : 14:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: -0.68%
H: 8.6%
C: 8.09%
disease alzheimer's
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
Published: 2023-11-06 (Crawled : 14:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 2.73%
H: 0.51%
C: -8.32%
disease alzheimer’s sciences program
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
Published: 2023-10-02 (Crawled : 13:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 0.36%
H: 1.98%
C: 0.6%
disease alzheimer’s sciences trial
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
Published: 2023-09-18 (Crawled : 13:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 4.02%
H: 0.3%
C: -8.96%
disease alzheimer’s review positive trials sciences
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
Published: 2023-09-13 (Crawled : 21:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 0.77%
H: 4.73%
C: 0.0%
drug candidate disease alzheimer’s publication sciences
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
Published: 2023-09-11 (Crawled : 13:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 0.47%
H: 2.78%
C: -1.51%
drug candidate disease alzheimer’s publication sciences
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
Published: 2023-07-05 (Crawled : 13:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 4.27%
H: 3.07%
C: -16.52%
disease alzheimer’s trial
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
Published: 2023-05-11 (Crawled : 12:20) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 0.0%
H: 6.03%
C: 3.18%
disease alzheimer’s sciences trial
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Published: 2023-02-08 (Crawled : 14:20) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 0.0%
H: 5.42%
C: -1.24%
treatment sciences disease alzheimer’s update
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
Published: 2023-01-24 (Crawled : 14:20) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: -6.97%
H: 1.97%
C: -13.16%
sciences disease alzheimer’s positive results study phase 2
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
Published: 2022-12-06 (Crawled : 14:20) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 0.0%
H: 4.56%
C: -0.36%
sciences disease alzheimer’s study
Global Alzheimer's Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
Published: 2022-01-04 (Crawled : 14:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.03%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 61.79%
H: 53.51%
C: 14.04%
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 1.61%
H: 2.11%
C: -1.07%
alzheimer therapeutics disease alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease
Published: 2021-12-23 (Crawled : 14:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 1.26%
H: 3.94%
C: 0.14%
alzheimer disease phase 3 alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Published: 2021-11-18 (Crawled : 14:30) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 3.02%
H: 6.04%
C: -0.1%
disease alzheimer treatment phase 3 alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Published: 2021-10-06 (Crawled : 13:15) - biospace.com/
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: -0.51%
H: 5.45%
C: -7.68%
disease alzheimer treatment phase 3 trial refocus-alz rethink-alz alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease
Published: 2021-09-22 (Crawled : 14:00) - biospace.com/
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 11.67%
H: 2.66%
C: -11.38%
disease alzheimer results topline alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Published: 2021-08-24 (Crawled : 13:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 5.88%
H: 0.78%
C: -3.74%
disease alzheimer treatment fda phase 3 alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s DiseasePhase 3 Study Initiation Still Expected Fall 2021
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 5.88%
H: 0.78%
C: -3.74%
disease alzheimer treatment fda phase 3 alzheimer’s alzheimer's
Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease
Published: 2021-07-29 (Crawled : 14:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 7.17%
H: 0.8%
C: -28.72%
disease alzheimer positive alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease
Published: 2021-07-29 (Crawled : 14:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K
|
Health Technology
|
| O: 7.17%
H: 0.8%
C: -28.72%
disease alzheimer positive alzheimer’s alzheimer's disease alzheimer's biomarkers
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.